Oruka Therapeutics (ORKA) Projected to Post Quarterly Earnings on Thursday

Oruka Therapeutics (NASDAQ:ORKA) is anticipated to announce its Q1 2025 earnings results before the market opens on Thursday, April 24th. Analysts expect the company to announce earnings of ($0.57) per share for the quarter.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Thursday, March 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.19. On average, analysts expect Oruka Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Oruka Therapeutics Stock Up 0.9 %

NASDAQ:ORKA opened at $9.30 on Tuesday. Oruka Therapeutics has a twelve month low of $5.49 and a twelve month high of $31.13. The company has a fifty day moving average of $10.10 and a 200-day moving average of $17.15. The firm has a market capitalization of $348.20 million, a P/E ratio of -1.49 and a beta of 0.47.

Insider Activity at Oruka Therapeutics

In related news, major shareholder Venrock Healthcare Capital Par acquired 88,794 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The stock was acquired at an average price of $11.44 per share, for a total transaction of $1,015,803.36. Following the completion of the acquisition, the insider now owns 4,148,428 shares of the company’s stock, valued at approximately $47,458,016.32. This represents a 2.19 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders purchased 98,339 shares of company stock valued at $1,128,456. 22.67% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts have recently commented on ORKA shares. HC Wainwright restated a “buy” rating and issued a $45.00 target price on shares of Oruka Therapeutics in a research note on Friday, February 7th. Wolfe Research initiated coverage on Oruka Therapeutics in a research note on Tuesday, February 4th. They issued an “outperform” rating and a $20.00 price objective for the company. Finally, Wedbush reaffirmed an “outperform” rating and set a $40.00 target price on shares of Oruka Therapeutics in a research report on Friday, March 7th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Oruka Therapeutics currently has an average rating of “Buy” and an average target price of $39.86.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.